Rituximab + 375 mg/m2 RRituximab
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Sep 1, 2006 → Aug 1, 2012
NCT ID
NCT00379587About Rituximab + 375 mg/m2 RRituximab
Rituximab + 375 mg/m2 RRituximab is a phase 1/2 stage product being developed by Biogen for Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00379587. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00379587 | Phase 1/2 | Completed |
Competing Products
20 competing products in Hematological Malignancies